Search

everythinglearnresearchcommunity

for

Search:↓

UV light causes skin color loss in bald areas; wear a cap and use sunscreen.

VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.

Alopecia areata and psoriasis vulgaris can inhibit each other in the same areas.

Hair density and thickness decrease in specific scalp areas in people with androgenetic alopecia.

Higher STAT3 levels are found in hair loss areas, but not linked to hair loss severity.

Alopecia areata affects about 2% of people and can impact any hair area.

A woman with a rare hair loss condition developed skin cancer in the bald area.

Frontal fibrosing alopecia is linked to four genetic areas, especially the HLA-B*07:02 allele.

Minoxidil effectively promotes hair regrowth in younger patients with small balding areas.

Certain proteins are found at higher levels in balding areas compared to non-balding areas, suggesting a link to hair loss. This could be useful for diagnosing and treating hair loss.

Nanofat injections may improve hair graft survival in scarred areas.

A rare skin reaction occurred when a man took paracetamol, causing a new rash in an area already affected by hair loss.

Hair loss in male frontal fibrosing alopecia may spare areas covered by a wristwatch.

The treatment combining platelet-rich plasma and a non-cross-linked hyaluronic acid compound significantly improved hair density and reduced bald areas in women with androgenetic alopecia, and it's safe with only mild side effects.

Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.

Alopecia areata affects hair follicle structure, even in non-balding areas.

A patient with hair loss condition grew excessive hair in areas covered by a cast.

Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.

Frontal fibrosing alopecia can be diagnosed by examining facial areas and treated with specific medications to stop its progression.

Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.

The review suggests the study on male pattern baldness needs to improve in areas like sample size, methodology, and bias for better quality and credibility.

Frontal fibrosing alopecia is increasingly affecting men, causing hair loss around the hairline and possibly other areas.

Sunscreen particles were not found in inflamed or fibrotic areas of skin in FFA patients, suggesting no direct link to the disease.

The report found a new type of hair loss in African-American women that affects more areas of the scalp than previously thought.

Alopecia areata was most common in people in their 30s and 40s, with some family history and a higher relapse rate, and larger bald areas responded better to specific immunotherapy.

The document concludes that both internal stem cell factors and external influences like the environment and hormones affect hair loss and aging, with potential treatments focusing on these areas.

New criteria for diagnosing frontal fibrosing alopecia include specific scalp and eyebrow hair loss as major factors and other hair loss areas and hair analysis as minor factors.

New factors in female hair loss include genetics, hormones, stress, and inflammation; future treatments should also focus on these areas and consider the patient's emotional well-being.

Intralesional triamcinolone is the most effective treatment for alopecia areata, followed by excimer light therapy, and then topical minoxidil. The scalp responds better to treatment than the beard area.

Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.